Market Overview

Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment

Share:
Related BMY
Activist Investors Are Back And More Active Than Ever
Jim Cramer: Maybe Investors Aren't Paying As Much For Corporate Earnings
Merck, Roche Gouge Bristol's I-O Share After Lung Cancer Approvals (Investor's Business Daily)
Related MRK
Breaking Down The Multiple Sclerosis 2017 Formularies: 'Stability Fares Well For The Market'
Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?
Merck to take $2.9B charge related to uprifosbuvir (Seeking Alpha)

Shares of Bristol-Myers Squibb (NYSE: BMY) fall 7.15% following Q4 results and management's announcement that the company will continue Phase 1 studies of nivolimab and Yervoy in lung cancer before advancing to Phase 3.

BMO Capital Markets analyst Alex Arfaei's noted that many investors expected a rapid advancement to stage 3 and this news will disappoint. Arfaei added that Bristol-Myer's management comments may be interpreted as a sign of caution.

The analyst reported that this news is “incrementally positive” for Merck & Co. (NYSE: MRK) who is developing a competing therapy in lung cancer, MK- 3475.

Arfaei rates Bristol-Myers as Market Perform with a $56.00 price target, and Merck as Outperform with a $56.00 price target.

Bristol-Myers is currently down 4.75% at $51.39 and shares of Merck are up 0.87% at $52.05.

Latest Ratings for BMY

DateFirmActionFromTo
Dec 2016JefferiesUpgradesHoldBuy
Oct 2016Hilliard LyonsUpgradesNeutralLong-Term Buy
Oct 2016Credit SuisseMaintainsNeutral

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: Alex Arfaei BMO Capital MarketsAnalyst Color News Analyst Ratings

 

Related Articles (BMY + MRK)

View Comments and Join the Discussion!